Mitsubishi Chemical Holdings (MCHC) has announced plans to buy the ‘dominant’ pharma-grade HPMC capsule maker Qualicaps as the global gelatin shortage continues.
Polypid says a new version of its lipid-polymer fusion-based technology has shown promise for the delivery of antibiotic in the treatment of bone fractures.
The bioavailability market lacks a leader that can offer comprehensive solutions according to Merck Millipore, which has set its sights on filling the gap through investments and a new lab.
Fujifilm has developed a new “pain-free” alternative to hypodermic needles which delivers drugs through a sheet of material covered in tiny dissolvable needles.
Marinomed Biotechnologies is set to take on the ‘common cold’ in China with a new patent for an anti-viral polymer technology that prevents rhinovirus infection.
Menarini has committed millions of euros to an antibody drug conjugate (ADC) clinical development and manufacturing pact with Oxford BioTerapeutics (OBT).
A medicated chewing gum prototype that combats motion sickness could give a platform to incorporate other active ingredients with objectionable tastes into gum.
A transdermal patch technology developed by 3M Drug Delivery could lead to new injection free, compliance-boosting treatments for postmenopausal osteoporosis.
Agricultural technology firm Monsanto has partnered with Complix NV to develop the latter’s protein therapeutic targeting technology for crop protection applications.
A new simplified analysis technique of the binding kinetics of membrane proteins could solve a host of drug delivery problems, according to scientists from the Arizona State University.
Vitamin B3 may be used to improve the efficacy of antibiotics when treating drug-resistant ‘superbug’ infections such as MRSA, according to new research.
New developments in the delivery space with Depomed signing up another Big Pharma licensee, Silence teaming up to test its tech for MiReven and Micropoint securing development funds for its microneedle system.
The first effective universal HIV vaccine may soon be on its way thanks to a family of highly potent (HP) antibodies which neutralise the virus, according to new findings.
A new hydrogel which can provide a sustained drug release of up to six months could cut diabetes dosage down from 365 injection per year to just two, according to researchers.
Tablet technology firm Accu-Break Pharmaceuticals has signed a product development and licensing agreement with Indian generic drugmaker Alembic Pharmaceuticals.
A new formulation of Genetech’s breast cancer drug Herceptin means patients could soon receive treatment via injection, rather than time consuming intravenous drip.
West Pharmaceutical Services is sticking with plans to lessen CMO (contract manufacturing organisation) activities and boost proprietary products despite a hefty uptick in contract production in Q2.
Reformulation and delivery tech firm SkyPharma is set for an earnings boost following US approval for rheumatoid arthritis (RA) drug developed by Horizon Pharma.
Hollow nano shells capable of holding both cancer fighting drugs and immune-system boosters could be the solution to oncology’s greatest delivery riddle, according to Yale University researchers.
Unilife has been granted a US patent for its prefilled syringe technology just weeks after announcing a supply contract with an unnamed autoimmune disease-focused pharma.
Prokarium – a biotech company that was formerly part of UK CMO Cobra Biologics spin-out - has bought an oral vaccine technology from Emergent BioSolutions.
Drug regulators and the biomanufacturing industry need to embrace drug delivery via the skin to solve solubility problems with peptides and proteins, according to Across Barriers’ Udo Bock.
